27 May 2019 - TLV has produced a health economic knowledge base for the regions of the drug Opdivo (nivolumab) in combination with Yervoy (ipilimumab). 

The knowledge base evaluates Opdivo in combination with Yervoy in the first line treatment of patients with advanced renal cell carcinoma.

TLV assesses the severity of the condition as very high as the disease lacks cure and leads to a significantly shortened life span with greatly impaired quality of life.

The uncertainty in the health economic analysis is considered to be high. This is mainly due to the uncertainty about how long patients will be treated with Opdivo. There is also uncertainty as to what effect treatment with Opdivo has after the time studied in the clinical studies. These have a significant impact on the cost per won quality adjusted life year. When TLV includes a stop rule regarding when treatment with Opdivo is terminated, the cost per quality-adjusted life year gained decreases.

Read TLV news (Swedish)